معرفی
Douglas Gin is an Adjunct Clinical Associate Professor in the Department of Medicine at Monash University and serves as Head of Unit leading the Dermatology Department at the Alfred Hospital, a top-tier tertiary teaching hospital in Victoria, Australia. With over 30 years of experience, he has been instrumental in training medical students and dermatology registrars, contributing significantly to clinical education and patient care.
His research interests are centered on medical dermatology, particularly psoriasis, eczema, vitiligo, and skin cancers. He has a strong focus on chemoprevention strategies, adverse drug reactions, and the integration of artificial intelligence in dermatological diagnosis. His work aligns with UN Sustainable Development Goals related to health and well-being.
The recent publications reflect a strong trend in translational research, combining clinical observation with innovative technology and preventive strategies. His work spans from case reports on novel drug reactions to large-scale multi-center trials and AI implementation studies, demonstrating a commitment to improving dermatological outcomes through evidence-based and technological advances.
Scientific Awards:
- Distinguished Services Award from Royal Australian College of General Practitioners (2014)
Grants and Research Projects: Actively involved as an Associate Investigator in the SiroSkin study (2022–2027), a multi-center trial evaluating topical sirolimus for preventing facial squamous cell carcinomas in organ transplant recipients. This project highlights his engagement in high-impact, collaborative clinical research.
Advising: While specific students are not listed, his long-standing role in teaching medical students and dermatology registrars at Alfred Hospital indicates a significant mentorship contribution. He also mentors GPs through extended educational outreach.
Labs and Teams: Douglas Gin collaborates within a broad network of dermatologists, oncologists, and researchers across Australia. He is part of the SMARTI Study Group and contributes to the Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR), indicating active participation in national dermatology research consortia.
